159 related articles for article (PubMed ID: 19499180)
1. Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation.
Yamazaki O; Ubara Y; Suwabe T; Nakanishi S; Hoshino J; Sawa N; Hayami N; Yamanouchi M; Takemoto F; Kenmei T; Masuoka K; Oohashi K
Clin Exp Nephrol; 2009 Oct; 13(5):522-525. PubMed ID: 19499180
[TBL] [Abstract][Full Text] [Related]
2. Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis.
Toriu N; Sawa N; Hiramatsu R; Mizuno H; Ikuma D; Sekine A; Hayami N; Sumida K; Yamanouchi M; Hasegawa E; Hoshino J; Takaichi K; Wake A; Ohashi K; Fujii T; Ubara Y
CEN Case Rep; 2020 Feb; 9(1):6-10. PubMed ID: 31522370
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.
Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088
[TBL] [Abstract][Full Text] [Related]
4. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
Hazenberg BP; Croockewit A; van der Holt B; Zweegman S; Bos GM; Delforge M; Raymakers RA; Sonneveld P; Vellenga E; Wijermans PW; von dem Borne PA; van Oers MH; de Weerdt O; Spoelstra FM; Lokhorst HM;
Haematologica; 2015 May; 100(5):677-82. PubMed ID: 25661441
[TBL] [Abstract][Full Text] [Related]
5. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation.
Gono T; Matsuda M; Dohi N; Hoshi K; Tada T; Sakashita K; Koike K; Aizawa M; Ikeda S
Intern Med; 2003 Jan; 42(1):72-7. PubMed ID: 12583623
[TBL] [Abstract][Full Text] [Related]
6. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support.
Sezer O; Schmid P; Shweigert M; Heider U; Eucker J; Harder H; Sinha P; Radtke H; Possinger K
Bone Marrow Transplant; 1999 May; 23(9):967-9. PubMed ID: 10338056
[TBL] [Abstract][Full Text] [Related]
7. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection.
Gono T; Matsuda M; Shimojima Y; Ishii W; Koyama J; Sakashita K; Koike K; Hoshii Y; Ikeda S
Amyloid; 2004 Dec; 11(4):245-56. PubMed ID: 15678759
[TBL] [Abstract][Full Text] [Related]
8. Vincristine, Doxorubicin, and Dexamethasone Induction before Autologous Stem Cell Transplantation in Patients with AL Amyloidosis: A Retrospective Comparison with Frontline Stem Cell Transplantation.
Iijima T; Sawa N; Nakayama Y; Oba Y; Ikuma D; Mizuno H; Yamanouchi M; Suwabe T; Wake A; Kono K; Hoshino J; Ubara Y; Ohashi K
Intern Med; 2022 Oct; 61(19):2853-2860. PubMed ID: 35228429
[TBL] [Abstract][Full Text] [Related]
9. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
10. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
11. The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
Iwadate D; Hasegawa E; Hoshino J; Hayami N; Sumida K; Yamanouchi M; Sekine A; Kawada M; Hiramatsu R; Suwabe T; Sawa N; Yuasa M; Wake A; Fujii T; Ohashi K; Takaichi K; Ubara Y
Intern Med; 2018 Mar; 57(5):701-706. PubMed ID: 29093408
[TBL] [Abstract][Full Text] [Related]
12. AL amyloidosis with IgD-lambda monoclonal gammopathy and lambda-type Bence-Jones protein: successful treatment by autologous stem cell transplantation.
Sakurai-Chin C; Ubara Y; Suwabe T; Hoshino J; Yonaha T; Hasegawa E; Sumida K; Hiramatsu R; Yamanouchi M; Hayami N; Yamauchi J; Tominaga N; Sawa N; Takemoto F; Masuoka K; Takaichi K; Oohashi K
Clin Exp Nephrol; 2010 Oct; 14(5):506-10. PubMed ID: 20632063
[TBL] [Abstract][Full Text] [Related]
13. High-dose melphalan followed by autologous stem cell support in primary systemic AL amyloidosis with multiple organ involvement.
Shimojima Y; Matsuda M; Ishii W; Koyama J; Yamamoto K; Shimodaira S; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):484-9. PubMed ID: 15942100
[TBL] [Abstract][Full Text] [Related]
14. Novel approaches to the treatment of primary amyloidosis.
Sezer O; Niemöller K; Jakob C; Langelotz C; Eucker J; Possinger K
Expert Opin Investig Drugs; 2000 Oct; 9(10):2343-50. PubMed ID: 11060811
[TBL] [Abstract][Full Text] [Related]
15. High-dose therapy and autologous transplantation in amyloidosis-AL.
Majolino I; Marcenò R; Pecoraro G; Scimé R; Vasta S; Liberti G; Rizzo A; Indovina A; Caronia F
Haematologica; 1993; 78(1):68-71. PubMed ID: 8098314
[TBL] [Abstract][Full Text] [Related]
16. [Three patients with primary AL amyloidosis treated by high-dose melphalan with autologous peripheral blood stem cell transplantation].
Mukai S; Kanashima H; Ogawa Y; Nakao T; Teshima H; Yamane T
Gan To Kagaku Ryoho; 2012 Apr; 39(4):625-7. PubMed ID: 22504689
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients.
Tazawa K; Matsuda M; Yoshida T; Gono T; Katoh N; Shimojima Y; Ishii W; Fushimi T; Koyama J; Ikeda S
Intern Med; 2008; 47(17):1517-22. PubMed ID: 18758127
[TBL] [Abstract][Full Text] [Related]
18. [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
Hosono N; Yamauchi T; Nakamura T; Yamashita T; Ueda T
Gan To Kagaku Ryoho; 2008 Mar; 35(3):533-7. PubMed ID: 18347412
[TBL] [Abstract][Full Text] [Related]
19. How to treat patients with systemic amyloid light chain amyloidosis? Comparison of high-dose melphalan, low-dose chemotherapy and no chemotherapy in patients with or without cardiac amyloidosis.
Hoshino J; Ubara Y; Sawa N; Sumida K; Hiramatsu R; Hasegawa E; Suwabe T; Hayami N; Yamanouchi M; Takemoto F; Taniguchi S; Takaichi K
Clin Exp Nephrol; 2011 Aug; 15(4):486-92. PubMed ID: 21387097
[TBL] [Abstract][Full Text] [Related]
20. Primary systemic amyloidosis.
Comenzo RL
Curr Treat Options Oncol; 2000 Apr; 1(1):83-9. PubMed ID: 12057064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
